IOB - Delayed Quote EUR

Pharma Mar, S.A. (0RC6.IL)

82.95
+2.60
+(3.24%)
At close: 5:07:43 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
175,747
174,855
158,153
196,343
229,831
Cost of Revenue
9,819
8,183
9,613
13,639
16,437
Gross Profit
165,928
166,672
148,540
182,704
213,394
Operating Expense
158,336
160,370
152,464
138,269
121,043
Operating Income
7,592
6,302
-3,924
44,435
92,351
Net Non Operating Interest Income Expense
848
3,196
1,687
-1,501
-3,003
Pretax Income
10,851
11,985
-3,623
43,790
95,129
Tax Provision
-9,025
-14,140
-4,760
-5,566
2,270
Net Income Common Stockholders
19,876
26,125
1,137
49,356
92,859
Diluted NI Available to Com Stockholders
19,876
26,125
1,137
49,356
92,859
Basic EPS
1.13
1.49
0.06
2.73
5.14
Diluted EPS
1.13
1.49
0.06
2.73
5.13
Basic Average Shares
17,302.89
17,539
17,900
18,050
18,070
Diluted Average Shares
17,302.89
17,562
17,916
18,063
18,085
Total Operating Income as Reported
7,682
6,468
-3,827
44,071
92,447
Rent Expense Supplemental
--
--
1,646
1,675
--
Total Expenses
168,155
168,553
162,077
151,908
137,480
Net Income from Continuing & Discontinued Operation
19,876
26,125
1,137
49,356
92,859
Normalized Income
19,813
25,989.25
913.50
51,045
92,754.55
Interest Income
-58
5,665
4,103
875
370
Interest Expense
4,542
2,469
2,416
2,376
3,373
Net Interest Income
848
3,196
1,687
-1,501
-3,003
EBIT
15,699
14,454
-1,207
46,166
98,502
EBITDA
22,914
21,227
4,549
52,066
104,085
Reconciled Cost of Revenue
9,819
8,183
9,613
13,639
16,437
Reconciled Depreciation
7,215
6,773
5,756
5,900
5,583
Net Income from Continuing Operation Net Minority Interest
19,876
26,125
1,137
49,356
92,859
Total Unusual Items Excluding Goodwill
105
181
298
-2,252
107
Total Unusual Items
105
181
298
-2,252
107
Normalized EBITDA
22,809
21,046
4,251
54,318
103,978
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
42
45.25
74.50
-563
2.55
12/31/2021 - 5/16/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ORYZF Oryzon Genomics S.A.
3.0300
0.00%
 
ORN.MU Oryzon Genomics SA
2.6200
0.00%
 
MAAT.PA MaaT Pharma SA
5.0000
+1.01%
 
ORN.F Oryzon Genomics S.A.
2.5650
-1.91%
 
NVV1.BE Novavax Inc
6.70
-2.94%
 
AVBP ArriVent BioPharma, Inc.
20.86
+7.80%
 
NVAX.MX Novavax, Inc.
150.71
-0.52%
 
ACE.ST Ascelia Pharma AB (publ)
4.1350
+6.85%
 
NVV1.F Novavax, Inc.
6.75
-1.75%
 
TTNP Titan Pharmaceuticals, Inc.
4.3500
-0.91%